Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: P135

    loading  Checking for direct PDF access through Ovid


Aim:To report our experience in complementing capecitabine with oxaliplatine in regard to tumour regression (efficacy), toxicity and surgical complications (safety) in thepreoperative treatment of locally advanced rectal cancer.Method:Ninety patients were studied, capecitabin (Xeloda) was administered to 60 patients (66.7%), while 30 patients (33.3%) also received Oxaliplatin (Xelox). Radiotherapy to a dose of 50.4 Gy over 5 weeks was administered. Time interval between radiochemotherapy and surgery was 8 weeks.Results:Gastrointestinal grade I-II toxicity was experienced by 23 patients (28.3% in Xeloda vs 20% Xelox). Grade III-IV toxicity was observed in further 18 patients (16.6% and 26.6% respectively). Skin and mucosa toxicity were experienced by 16 patients, 12 (20% in Xeloda and 13.3% in the Xelox arm). Good responders (Mandard Grades 1-2) were observed in 21 patients (35% Xeloda vs 50% Xelox). Major complications with necessary reoperation were seen in 11 patients (representing 10% in the Xeloda arm and 16.7% in the Xelox); minor complications were observed in 31 patients (35% and 33% respectively).Conclusion:Preoperative radiochemotherapy with capecitabin is safe and effective. Adding oxaliplatine to capecitabine shows an increase in good response rate to 50%, adding some more toxicity and surgical complications.

    loading  Loading Related Articles